Literature DB >> 19744717

Complete local elimination of infectious trachoma from severely affected communities after six biannual mass azithromycin distributions.

Jesse B Biebesheimer1, Jenafir House, Kevin Cyrus Hong, Takele Lakew, Wondu Alemayehu, Zhaoxia Zhou, Jeanne Moncada, Andrew Rogér, Jeremy Keenan, Bruce D Gaynor, Julius Schachter, Thomas M Lietman.   

Abstract

OBJECTIVE: To determine whether infectious trachoma can be completely eliminated from severely affected villages.
DESIGN: Cross-sectional survey of 2 villages previously enrolled and monitored over 42 months as part of a larger, group-randomized clinical trial. PARTICIPANTS: A total of 758 individuals residing in 2 villages with high baseline trachoma prevalence, of a total population of 768 (98.7%).
METHODS: All members of the 2 villages were offered 6 biannual mass treatments with oral azithromycin. At 42 months, each current village member was examined. The right upper tarsal conjunctiva was everted and swabbed. Samples were processed for evidence of Chlamydia trachomatis RNA. MAIN OUTCOME MEASURES: Clinical activity by World Health Organization simplified grading scale for trachoma and laboratory evidence of chlamydial RNA.
RESULTS: Average antibiotic coverage over the study period was 90% and 94% in the 2 villages. Clinical trachoma activity in children aged 1 to 5 years decreased from 78% and 83% in the 2 villages before treatment to 17% and 24% at 42 months. Polymerase chain reaction (PCR) evidence of infection in the same age group decreased from 48% to 0% in both villages at 42 months. When all age groups were examined, there were zero cases with evidence of chlamydial RNA among 758 total villagers tested.
CONCLUSIONS: Biannual mass distribution of azithromycin can locally eliminate ocular chlamydial infection from severely affected communities.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19744717     DOI: 10.1016/j.ophtha.2009.04.041

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  23 in total

1.  The epidemiological dynamics of infectious trachoma may facilitate elimination.

Authors:  Thomas M Lietman; Teshome Gebre; Berhan Ayele; Kathryn J Ray; M Cyrus Maher; Craig W See; Paul M Emerson; Travis C Porco
Journal:  Epidemics       Date:  2011-04-06       Impact factor: 4.396

2.  Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions.

Authors:  Jeremy D Keenan; Craig W See; Jeanne Moncada; Berhan Ayele; Teshome Gebre; Nicole E Stoller; Charles E McCulloch; Travis C Porco; Bruce D Gaynor; Paul M Emerson; Julius Schachter; Thomas M Lietman
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-01-25       Impact factor: 4.799

3.  Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma.

Authors:  Jeremy D Keenan; Berhan Ayele; Teshome Gebre; Jeanne Moncada; Nicole E Stoller; Zhaoxia Zhou; Travis C Porco; Charles E McCulloch; Bruce D Gaynor; Paul M Emerson; Julius Schachter; Thomas M Lietman
Journal:  Clin Infect Dis       Date:  2011-11-17       Impact factor: 9.079

4.  "Manifesto" for advancing the control and elimination of neglected tropical diseases.

Authors:  Peter J Hotez; Bernard Pecoul
Journal:  PLoS Negl Trop Dis       Date:  2010-05-25

5.  Profound and sustained reduction in Chlamydia trachomatis in The Gambia: a five-year longitudinal study of trachoma endemic communities.

Authors:  Matthew J Burton; Martin J Holland; Pateh Makalo; Esther A N Aryee; Ansumana Sillah; Sandra Cohuet; Angels Natividad; Neal D E Alexander; David C W Mabey; Robin L Bailey
Journal:  PLoS Negl Trop Dis       Date:  2010-10-05

6.  Eradicating blinding trachoma: What is working?

Authors:  Imtiaz A Chaudhry
Journal:  Saudi J Ophthalmol       Date:  2009-12-21

7.  Risk factors for ocular infection with Chlamydia trachomatis in children 6 months following mass treatment in Tanzania.

Authors:  Luis Carlos Cajas-Monson; Harran Mkocha; Beatriz Muñoz; Thomas C Quinn; Charlotte A Gaydos; Sheila K West
Journal:  PLoS Negl Trop Dis       Date:  2011-03-15

8.  Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster-randomized clinical trial.

Authors:  Alison H Skalet; Vicky Cevallos; Berhan Ayele; Teshome Gebre; Zhaoxia Zhou; James H Jorgensen; Mulat Zerihun; Dereje Habte; Yared Assefa; Paul M Emerson; Bruce D Gaynor; Travis C Porco; Thomas M Lietman; Jeremy D Keenan
Journal:  PLoS Med       Date:  2010-12-14       Impact factor: 11.069

Review 9.  Will the SAFE strategy be sufficient to eliminate trachoma by 2020? Puzzlements and possible solutions.

Authors:  Diane K Lavett; Van C Lansingh; Marissa J Carter; Kristen A Eckert; Juan C Silva
Journal:  ScientificWorldJournal       Date:  2013-05-19

10.  Assessment of transmission in trachoma programs over time suggests no short-term loss of immunity.

Authors:  Fengchen Liu; Travis C Porco; Kathryn J Ray; Robin L Bailey; Harran Mkocha; Beatriz Muñoz; Thomas C Quinn; Thomas M Lietman; Sheila K West
Journal:  PLoS Negl Trop Dis       Date:  2013-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.